Exercise Following Autologous Peripheral Blood Stem Cell Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00883961
Recruitment Status : Unknown
Verified December 2009 by Charite University, Berlin, Germany.
Recruitment status was:  Recruiting
First Posted : April 20, 2009
Last Update Posted : December 23, 2009
Information provided by:
Charite University, Berlin, Germany

Brief Summary:
The study evaluates the effects of a supervised exercise program on the physical performance, the mood and the complications of therapy in patients undergoing a high-dose chemotherapy followed by an autologous peripheral blood stem cell transplantation.

Condition or disease Intervention/treatment Phase
Hematological Disease Other: Supervised exercise Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Supportive Care
Study Start Date : December 2009
Estimated Primary Completion Date : April 2011
Estimated Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Supervised exercise Other: Supervised exercise
The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.

No Intervention: Control group
The patients will not carry out a structured exercise program.

Primary Outcome Measures :
  1. VO2max [ Time Frame: At recruitment and after 3 weeks ]

Secondary Outcome Measures :
  1. Mood [ Time Frame: At recruitment and after 3 weeks ]
  2. Duration of aplasia [ Time Frame: 3 weeks ]
  3. Complications during hospitalization [ Time Frame: 3 weeks ]
  4. Need for transfusion of platelets and red blood cells [ Time Frame: 3 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-70
  • Hematological disease
  • Treatment with high-dose chemotherapy followed by autologous stem cell transplantation
  • Understanding of written German

Exclusion Criteria:

  • Cardiorespiratory, metabolical, osteoarticular or immunological diseases which can be aggravated by exercise
  • Pathological stress-ECG at admission

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00883961

Contact: Fernando Dimeo, MD +493084452098

Section Sports Medicine, Charité Universitätsmedizin Berlin, Hindenburgdamm 30 Recruiting
Berlin, Germany, 12200
Contact: Fernando Dimeo, MD         
Principal Investigator: Fernando Dimeo, MD         
Sponsors and Collaborators
Charite University, Berlin, Germany
Principal Investigator: Fernando Dimeo, MD Charite University, Berlin, Germany

Responsible Party: Dr. Fernando Dimeo, Dept. of Sports Medicine, Charité Universitätsmedizin Berlin Identifier: NCT00883961     History of Changes
Other Study ID Numbers: EA4/029/09
First Posted: April 20, 2009    Key Record Dates
Last Update Posted: December 23, 2009
Last Verified: December 2009

Keywords provided by Charite University, Berlin, Germany:
High-dose chemotherapy
Hematological neoplasties
Hematologic neoplastic disorders

Additional relevant MeSH terms:
Hematologic Diseases